Insider Selling: Pharvaris (NASDAQ:PHVS) Director Sells $881,402.40 in Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan sold 29,070 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $30.32, for a total transaction of $881,402.40. Following the completion of the sale, the director owned 355,167 shares in the company, valued at $10,768,663.44. The trade was a 7.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Wednesday, April 29th, Johannes Gerardus Chri Schikan sold 3,830 shares of Pharvaris stock. The stock was sold at an average price of $30.07, for a total transaction of $115,168.10.
• On Thursday, April 23rd, Johannes Gerardus Chri Schikan sold 100 shares of Pharvaris stock. The stock was sold at an average price of $30.03, for a total transaction of $3,003.00.
• On Wednesday, April 22nd, Johannes Gerardus Chri Schikan sold 7,000 shares of Pharvaris stock. The stock was sold at an average price of $30.05, for a total transaction of $210,350.00.

Pharvaris Price Performance

NASDAQ:PHVS opened at $29.44 on Monday. The firm has a market capitalization of $1.93 billion, a P/E ratio of -8.74 and a beta of -2.34. Pharvaris N.V. has a 1-year low of $14.59 and a 1-year high of $31.14. The company’s fifty day moving average price is $27.62 and its 200-day moving average price is $26.09.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Friday, April 3rd. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.15). Equities analysts anticipate that Pharvaris N.V. will post -3.19 EPS for the current fiscal year.

Key Headlines Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Insiders still retain large, meaningful stakes after the sales, which can indicate alignment with shareholders and limit the likelihood of continued big disposals. Examples: director Johannes Schikan remains a large shareholder (~355k shares after sales) and others still hold six‑figure stakes. SEC Filing
• Neutral Sentiment: Commentary noting that director sales may matter less than upcoming company catalysts — suggests investors should watch near‑term clinical/regulatory milestones rather than focus only on the trades. For Pharvaris Investors, the Director’s Sale Matters Less Than What’s Coming Next
• Negative Sentiment: Anne Lesage sold multiple blocks (3,700; 19,200; 21,700 shares) across April 29–30 at ≈$30.08–$30.26, reducing her position by as much as ~27.8% in filings and generating >$1.34M in proceeds — a signal that prompted selling pressure. SEC Filing
• Negative Sentiment: Peng Lu executed two sales (3,733 and 15,000 shares) on April 29–30 at ≈$30.06–$30.24, cutting ownership by up to ~18.5% and raising roughly $565.8k — another substantial insider liquidity event. SEC Filing
• Negative Sentiment: Director Johannes Gerardus Chri Schikan sold two blocks (3,830 and 29,070 shares) on April 29–30 at ≈$30.07–$30.32, a ~7.6% cut in his holdings and ~ $996.6k in disclosed proceeds — adding to the overall sell pressure. SEC Filing

Analyst Ratings Changes

PHVS has been the topic of a number of recent analyst reports. Royal Bank Of Canada lowered their price target on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. Citigroup reissued a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Pharvaris in a report on Tuesday, March 3rd. Finally, Wedbush increased their price target on shares of Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $42.73.

Hedge Funds Weigh In On Pharvaris

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PHVS. Geode Capital Management LLC lifted its holdings in Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after purchasing an additional 15,769 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter. Legal & General Group Plc lifted its holdings in Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares in the last quarter. Amundi lifted its holdings in Pharvaris by 2,741,600.0% during the second quarter. Amundi now owns 27,417 shares of the company’s stock valued at $489,000 after purchasing an additional 27,416 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in Pharvaris by 19.2% during the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock valued at $860,000 after purchasing an additional 7,879 shares in the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.